KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt RepaymentsNon-Current ReceivablesOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShort-Term Debt issuances
Ratios

Astrazeneca (AZN) Non-Current Receivables (2016 - 2025)

Historic Non-Current Receivables for Astrazeneca (AZN) over the last 13 years, with Q4 2025 value amounting to $1.3 billion.

  • Astrazeneca's Non-Current Receivables rose 4268.82% to $1.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 billion, marking a year-over-year increase of 4268.82%. This contributed to the annual value of $1.3 billion for FY2025, which is 4268.82% up from last year.
  • Astrazeneca's Non-Current Receivables amounted to $1.3 billion in Q4 2025, which was up 4268.82% from $1.2 billion recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's Non-Current Receivables ranged from a high of $1.3 billion in Q4 2025 and a low of $549.0 million during Q1 2021
  • In the last 5 years, Astrazeneca's Non-Current Receivables had a median value of $823.0 million in 2021 and averaged $853.2 million.
  • In the last 5 years, Astrazeneca's Non-Current Receivables surged by 6205.57% in 2021 and then tumbled by 2106.48% in 2023.
  • Over the past 5 years, Astrazeneca's Non-Current Receivables (Quarter) stood at $895.0 million in 2021, then decreased by 6.7% to $835.0 million in 2022, then decreased by 3.83% to $803.0 million in 2023, then grew by 15.82% to $930.0 million in 2024, then soared by 42.69% to $1.3 billion in 2025.
  • Its last three reported values are $1.3 billion in Q4 2025, $1.2 billion for Q3 2025, and $1.1 billion during Q2 2025.